| A Gene Transfer Study for Hemophilia A (NCT03003533) | Spark Therapeutics, Inc. | 2017-01-26 |
| German Pediatric Hemophilia Research Database (NCT02912143) | Goethe University | 2017-01-01 |
| Comparison of Ideal vs. Actual Weight Base Factor Dosing (NCT03286153) | Bloodworks | 2017-01-01 |
| BAX 802 in CHA With Inhibitors (NCT02895945) | Baxalta now part of Shire | 2016-12-22 |
| UK - EHL Outcomes Registry (NCT02938156) | Royal Free Hospital NHS Foundation Trust | 2016-12-17 |
| Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products (NCT02976753) | Swedish Orphan Biovitrum | 2016-12-01 |
| Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A (NCT03915080) | Lund University | 2016-12-01 |
| Drug Use Investigation of Kovaltry in Hemophilia A Patients (NCT02941783) | Bayer | 2016-11-30 |
| Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT® (NCT03006965) | Spanish Society of Thrombosis and Haemostasis | 2016-11-11 |
| Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A (NCT02921945) | Sinocelltech Ltd. | 2016-10-01 |
| A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (NCT02847637) | Hoffmann-La Roche | 2016-09-27 |
| The Hemophilia Ultrasound Project (NCT02807753) | University of Miami | 2016-09-16 |
| Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A (NCT02888223) | Sinocelltech Ltd. | 2016-09-01 |
| GAS-Hem Feasibility Study (NCT02674997) | Baxalta now part of Shire | 2016-08-05 |
| Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients (NCT02622646) | Hospital Universitario La Fe | 2016-08-01 |
| Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A (NCT02930317) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2016-08-01 |
| A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors (NCT02795767) | Hoffmann-La Roche | 2016-07-22 |
| Improved Factor VIII Inhibitor Evaluation (NCT02726139) | Boston VA Research Institute, Inc. | 2016-07-15 |
| Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A." (NCT02581969) | Bayer | 2016-04-14 |
| Virtual Reality for Hemophilia (NCT03507582) | Nationwide Children's Hospital | 2016-04-01 |
| Could Physical Activity Help to Counteract the Blood Haemophilia Disturbance? A Pilot Study. (NCT02851082) | University Hospital, Toulouse | 2016-04-01 |
| Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Patients With Hemophilia (NCT02750085) | Victor Blanchette | 2016-04-01 |
| BAX 826 Dose-Escalation Safety Study (NCT02716194) | Baxalta now part of Shire | 2016-03-03 |
| Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study (NCT02740413) | Pfizer | 2016-01-11 |
| Ultrasonography in Hemophilic Joint Disease and Serum Markers (NCT02634918) | Northwell Health | 2016-01-01 |
| Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A (NCT02634723) | Baxalta now part of Shire | 2015-12-23 |
| Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (NCT02396862) | Bayer | 2015-12-09 |
| BAX 855 PK-guided Dosing (NCT02585960) | Baxalta now part of Shire | 2015-11-23 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (NCT02622321) | Hoffmann-La Roche | 2015-11-18 |
| A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A (NCT02615691) | Baxalta now part of Shire | 2015-11-12 |
| A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors (NCT02571569) | Bayer | 2015-10-28 |
| An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B (NCT02554773) | Genzyme, a Sanofi Company | 2015-09-18 |
| National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A (NCT02528968) | Hampshire Hospitals NHS Foundation Trust | 2015-09-01 |
| Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers (NCT02506023) | Emory University | 2015-07-01 |
| Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A (NCT02461992) | Pfizer | 2015-07-01 |
| Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes (NCT02392156) | Bioverativ Therapeutics Inc. | 2015-07-01 |
| Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate (NCT02483208) | Bayer | 2015-06-01 |
| A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment (NCT02476942) | Hoffmann-La Roche | 2015-05-26 |
| Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients (NCT02727647) | Chulalongkorn University | 2015-05-01 |
| A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B (NCT02418793) | OPKO Health, Inc. | 2015-05-01 |
| PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A (NCT02492984) | Pfizer | 2015-04-01 |
| Platelet Function in Patients With Hemophilia A (NCT02093065) | Boston Children's Hospital | 2015-03-01 |
| Colorado Adult Joint Assessment Scale (CAJAS) Validation (NCT02284789) | Bayer | 2015-02-01 |
| 2-cohort Study of Adult Patients With Severe Hemophilia A in Greece (NCT02319070) | Bayer | 2015-01-13 |
| An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A (NCT02234323) | Bioverativ, a Sanofi company | 2015-01-12 |
| Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients (NCT02479087) | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 2015-01-01 |
| Web-based Application for the Population Pharmacokinetic Service - Phase 1 (NCT02061072) | McMaster University | 2015-01-01 |
| Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ (NCT02962765) | Octapharma | 2015-01-01 |
| Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A (NCT02282410) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2014-12-01 |
| Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A (NCT02280265) | Nanjing Medical University | 2014-11-01 |
| BAX 855 Pediatric Study (NCT02210091) | Baxalta now part of Shire | 2014-10-31 |
| An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A (NCT02172950) | CSL Behring | 2014-10-13 |
| Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis (NCT02263066) | Bayer | 2014-10-01 |
| Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function (NCT02225483) | CancerCare Manitoba | 2014-09-01 |
| Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS (NCT02190149) | Baxalta now part of Shire | 2014-07-22 |
| China ADVATE PTP Study (NCT02170402) | Baxalta now part of Shire | 2014-06-26 |
| Individualizing Hemophilia Prophylaxis Using Thromboelastography (NCT02582060) | Children's Hospital Los Angeles | 2014-05-20 |
| Evaluation of Clot Stability Induced by Solulin: Evaluation of New Solulin Mutants Lacking Protein C Activation Capacity (NCT02911233) | University Hospital, Caen | 2014-03-01 |
| Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A (NCT01790828) | Pfizer | 2014-02-01 |
| A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients (NCT02035605) | Sanofi | 2014-01-20 |
| Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A (NCT02027779) | Green Cross Corporation | 2014-01-01 |
| Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures (NCT01913405) | Baxalta now part of Shire | 2013-12-20 |
| BAX 855 Continuation (NCT01945593) | Baxalta now part of Shire | 2013-10-15 |
| ADVATE 2 mL Post-Authorization Safety Surveillance (PASS) (NCT02093741) | Baxalta now part of Shire | 2013-09-20 |
| An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia (NCT02199717) | The Hospital for Sick Children | 2013-09-01 |
| Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A (NCT01775618) | Bayer | 2013-05-29 |
| Prophylaxis Versus on Demand Treatment for Children With Hemophilia A (NCT01810666) | Bayer | 2013-03-01 |
| Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease (NCT02061033) | Karolinska University Hospital | 2013-03-01 |
| Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador (NCT01589848) | Universidad del Azuay | 2013-03-01 |
| Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A (NCT01619046) | Green Cross Corporation | 2013-03-01 |
| Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen (NCT01757405) | Baxalta now part of Shire | 2013-02-20 |
| Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study) (NCT01736475) | Baxalta now part of Shire | 2013-01-31 |
| Comparison of Prophylaxis and On-demand Treatment in Children With Moderate to Severe Hemophilia A (NCT02362581) | Chulalongkorn University | 2012-12-01 |
| Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development (NCT01445197) | CSL Behring | 2012-12-01 |
| Viscosupplementation in Patients With Hemophilic Arthropathy (NCT01748201) | University of Sao Paulo General Hospital | 2012-11-01 |
| Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A (NCT01458106) | Bioverativ Therapeutics Inc. | 2012-11-01 |
| Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC) (NCT01579903) | Pfizer | 2012-08-01 |
| Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222 (NCT01653639) | Bayer | 2012-07-01 |
| Personalized Prediction of Tolerance and Immunogenicity in Hemophilia (NCT01626105) | Victor J Marder, M.D. | 2012-06-01 |
| A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A (NCT01580293) | Bayer | 2012-04-23 |
| An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A (NCT01486927) | CSL Behring | 2012-02-01 |
| Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia (NCT01439971) | Catalyst Biosciences | 2011-12-01 |
| Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A (NCT01454739) | Bioverativ Therapeutics Inc. | 2011-12-01 |
| Internet-based Educational Program to Promote Self-Management for Teens With Hemophilia (NCT01477437) | The Hospital for Sick Children | 2011-11-01 |
| Inhibitor Development in Patients With Hemophilia A Undergoing Surgery (NCT01571934) | Emory University | 2011-11-01 |
| Osteoporosis and MRI Study in Hemophilia (NCT01460147) | Baxalta now part of Shire | 2011-10-30 |
| Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A (NCT01434511) | Baxalta now part of Shire | 2011-10-03 |
| BAX 855 Dose-Escalation Safety Study (NCT01599819) | Baxalta now part of Shire | 2011-09-30 |
| Early Prophylaxis Immunologic Challenge (EPIC) Study (NCT01376700) | Baxalta now part of Shire | 2011-08-26 |
| Hemophilia Inhibitor Previously Untreated Patient Study (NCT01652027) | The University of Texas Health Science Center, Houston | 2011-07-01 |
| Kogenate FS Regulatory Post-Marketing Surveillance (NCT01386268) | Bayer | 2011-06-01 |
| Socialization of Adult Men With Congenital Hemophilia A or B (NCT01510418) | Dana-Farber Cancer Institute | 2011-05-01 |
| A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A (NCT01233258) | Bayer | 2011-01-01 |
| Biomarkers Serum Collection Methodology Pilot Study (NCT01318707) | Georgetown University | 2010-12-01 |
| Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration (NCT01184820) | Bayer | 2010-10-13 |
| Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World (NCT01217255) | The Hospital for Sick Children | 2010-09-01 |
| Study of Biostate® in Children With Hemophilia A (NCT01229007) | CSL Behring | 2010-08-01 |
| Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A (NCT00989196) | Octapharma | 2010-05-01 |
| Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia (NCT01090206) | Virginia Commonwealth University | 2010-03-01 |
| Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting (NCT00950170) | Pfizer | 2010-02-10 |